34 results about "Bone cancer" patented technology

The invention discloses a magnetic resonance guided focusing microwave brain tumor thermal ablation system and a focusing adjustment method. According to the invention, three-dimensional data of MRI and CT are integrated, microwave frequency suitable for tumor size and depth is selected, and an appropriate antenna and cross polarized antenna phased array is designed. The output power and phase of the antenna are optimized by using a differential evolution algorithm, accurate focusing of microwave energy is realized, the tumor temperature is increased to an ablation level, and meanwhile, the safe temperature of healthy tissues is kept. The system effectively inhibits adverse effects of brain tissues including skull on microwave penetration, and realizes accurate ablation of tumors through combination of a small number of antennas and an iterative algorithm. MRI guidance and real-time temperature monitoring are combined, so that the accuracy and safety of thermal ablation are ensured, the brain tumor is radically treated in a non-invasive manner, and the problem that the medicine cannot penetrate through the blood brain barrier is solved. In addition, the technology can also be used for treating liver cancer, pancreatic cancer, thyroid cancer, breast cancer, kidney cancer, bone cancer, bladder cancer, gallbladder cancer and other diseases.

The invention relates to the technical field of medical instruments, in particular to a bone wax sealing assistor for an osteocarcinoma pain model, which is characterized in that a supporting mechanism is arranged on the outer ring wall of a positioning ring, and a first annular slide rail in the supporting mechanism is fixed on the outer ring wall of the positioning ring; the multiple supporting plates are connected with the first annular sliding rail. The steering mechanism is arranged in the positioning ring; a fixed internal thread pipe in the steering mechanism is arranged in the positioning ring; the fixing mechanism is arranged in the steering mechanism; an adjusting threaded pipe in the fixing mechanism is screwed in a fixed inner threaded pipe through threads; a through hole is formed in the bottom of the adjusting threaded pipe; according to the practical situation of an operation area, an injector can be stably inserted into a needed position, bone wax is used for sealing a needle hole quickly, accurately and effectively, bone wax filling can reach a certain depth, and cancer cells are prevented from overflowing; injectors of different models and sizes can be fixed in the adjusting threaded pipe, the stability of the injectors in the using process is improved, and the using range is wide.

The present application relates to the field of polymer chemistry and biomedical technology, and particularly relates to a macrocyclic lactone polymer shown in formula (I) which is used for preventing or treating hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, gastric cancer, lung cancer, Barrett's esophageal cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymphoma, kidney cancer, brain cancer, nerve cancer, nasopharyngeal cancer, oral cancer, bladder cancer, colorectal cancer and melanoma, and has the potential to be developed into a new type of antitumor drug.

The ester derivatives of brefeldin A represented by Formula (I) in the inhibition of tumor proliferation. The compounds are prominent in the prevention or treatment of hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, gastric cancer, lung cancer, Bart's esophageal cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymphoma, kidney cancer, brain cancer, nerve cancer, nasopharyngeal cancer, oral cancer and colorectal cancer, and have the potential to be developed as antitumor agents.

Disclosed is an mIDH1 / NAMPT dual-target inhibitor, which is selected from a compound having a structure as shown in formula (I) or formula (II), or a pharmaceutically acceptable salt, racemate, stereoisomer, prodrug, or solvent compound thereof. The dual-target inhibitor of the present invention can effectively overcome the shortcomings of a single mIDH1 inhibitor and single NAMPT inhibitor having poor efficacy against solid tumors. Said inhibitor can inhibit the malignant proliferation of tumors, has a good therapeutic effect, has low toxicity, and can penetrate the blood-brain barrier, and it is not easy to acquire drug resistance to said inhibitor. Moreover, the inhibitor can be used to prepare a medicament for treating cancer or tumor-related diseases, the cancer or tumor-related diseases comprising multiple myeloma, leukemia, breast cancer, prostate cancer, lung cancer, liver cancer, gastric cancer, bone cancer, brain cancer, head and neck cancer, intestinal cancer, pancreatic cancer, bladder cancer, testicular cancer, ovarian cancer, and endometrial cancer.

The invention relates to the field of biological detection, and discloses a plasma polypeptide marker COL1A2 related to tumor bone metastasis and pain and application. Aiming at the problem that early diagnosis of bone cancer pain and tumor bone metastasis is difficult, by detecting the level of circulating COL1A2 in plasma, it is found that the circulating COL1A2 is remarkably up-regulated in patients with tumor bone metastasis and bone cancer pain and is remarkably related to clinical pain score and tumor staging. A sensitive and specific COL1A2 detection method is established by adopting an enzyme-linked immunosorbent assay (ELISA) technology, and occurrence and staging of bone cancer pain and tumor bone metastasis can be identified with high prediction efficiency that AUC is 0.95 and 0.94 respectively. The method is low in detection cost, simple and convenient to operate and suitable for clinical popularization and application, and scientific basis and technical support are provided for screening of high-risk groups, early diagnosis of bone metastasis, pain staging and personalized treatment. The invention has important significance for optimizing diagnosis and treatment strategies of patients suffering from bone cancer pain and improving clinical transformation efficiency.

This invention relates to the field of biological testing and discloses a plasma polypeptide marker, COL1A2, associated with tumor bone metastasis and pain, and its applications. To address the difficulties in early diagnosis of bone cancer pain and tumor bone metastasis, this study examined circulating COL1A2 levels in plasma and found that it was significantly upregulated in patients with bone metastasis and pain, and correlated significantly with clinical pain scores and tumor stage. Using enzyme-linked immunosorbent assay (ELISA) technology, a sensitive and specific COL1A2 detection method was established, capable of identifying the occurrence and stage of bone cancer pain and tumor bone metastasis with high predictive efficacy of 0.95 and 0.94, respectively. This assay is low-cost and simple to operate, making it suitable for clinical application. It provides scientific basis and technical support for screening high-risk populations, early diagnosis of bone metastasis, pain staging, and personalized treatment. This invention is of great significance for optimizing diagnostic and treatment strategies for patients with bone cancer pain and improving clinical translation efficiency.

The invention discloses oligopeptide and application thereof in preparation of a medicine for treating and / or relieving pain. The amino acid sequence of the oligopeptide disclosed by the invention comprises a derivative sequence formed by additionally arranging 1-3 amino acids at the N end and / or C end of the amino acid sequence shown as Tyr-Pro-Arg, especially Tyr-Pro-Arg-Arg (YPRR, YR4), and a gastrointestinal tract digestion product Tyr-Pro-Arg (YPR, YR3) of the oligopeptide. The oligopeptide not only can relieve acute pain induced by a mouse thermal drifting model, but also can relieve chronic pain induced by a rat sciatic nerve chronic compression injury model and a tibia bone cancer pain model, and meanwhile, the oligopeptide obviously inhibits CCI-induced spinal astrocyte, microglia and neuron activation; therefore, the compound has important development and application values in the aspects of central sensitization inhibition and analgesia.

The invention relates to the technical field of medicines, in particular to application of anwuligan in preparation of medicines for treating or preventing neuroinflammation related diseases and bone cancer pain. Animal experiments prove that the anwuligan can relieve nerve cell inflammatory response, inhibit tumor cell growth, prevent bone destruction caused by tumors and inhibit mechanical pain sensitivity, heat pain sensitivity and spontaneous pain of bone cancer pain rats. Results show that the anwuligan has potential anti-inflammatory, anti-cancer and analgesic effects and has an application prospect of being developed into a medicine for preventing and treating cancer pain.

The present invention relates to compositions and methods of treating L0XHD1- associated diseases and disorders (e.g., bone cancer, such as Ewing Sarcoma). In some embodiments, the present invention also relates to T cell receptors that bind to specific L0XHD1 peptide fragments in the context of specific HLA types. In some embodiments, the present invention relates to nucleic acid molecules encoding said T cell receptors. In other embodiments, the present invention relates to cells modified to express said T cell receptors or nucleic acid molecules encoding thereof.

This patent application belongs to the field of antibody technology, specifically relating to an anti-NGF monoclonal antibody and its applications. The anti-NGF monoclonal antibody of this patent application can specifically bind to TrkA and p75. The anti-NGF monoclonal antibody of this patent application can be used to treat or prevent NGF-mediated diseases, such as autoimmune arthritis, bone cancer pain, osteoarthritis, and fracture pain.

The present invention relates to a non-invasive magneto-acoustic apparatus for healthy tissue healing and cancer regression comprising at least one pulsed ultrasound unit (LIPUS), at least one permanent magnet, at least one module housing, at least one permanent magnets, at least one control system for controlling pulsed ultrasound unit to energize the unit with desired pulse duration, intensity and active / ON time. The invention is to synchronously use the low intensity pulsed ultrasound (LIPUS) and static magnetic field (SMF) to selectively activate cellular activities specific to cartilage, bone, skin leading to accelerated tissue healing, regeneration. The invention apparatus is to inhibit cancer cellular activities specific to cancers of breast, skin, bone leading to enhanced cancer regression, while leaving the healthy cells unaffected using magneto-acoustic apparatus appropriately. The apparatus exhibit no toxicity to healthy cells and can reduce overall treatment time and costs due to accelerated tissue repair and tumor regression.

The present invention discloses a magnetic resonance-guided focused microwave brain tumor thermal ablation system and a focusing adjustment method. The present invention integrates the three-dimensional data of MRI and CT, selects the microwave frequency suitable for the size and depth of the tumor, and designs a suitable antenna and a cross-polarized antenna phased array. The differential evolution algorithm is used to optimize the antenna output power and phase to achieve precise focusing of microwave energy, increase the tumor temperature to the ablation level, and maintain the safe temperature of healthy tissue. The system effectively suppresses the adverse effects of brain tissue, including the skull, on microwave penetration, and achieves precise ablation of tumors through a small number of antennas combined with an iterative algorithm. Combined with MRI guidance and real-time temperature monitoring, the accuracy and safety of thermal ablation are ensured, non-invasive radical treatment of brain tumors is achieved, and the problem of drugs being unable to penetrate the blood-brain barrier is overcome. In addition, this technology can also be used to treat other diseases such as liver cancer, pancreatic cancer, thyroid cancer, breast cancer, kidney cancer, bone cancer, bladder cancer, and gallbladder cancer.

The invention belongs to the field of medicine, and particularly relates to application of a benzothiazepine compound to preparation of a medicine for treating cancer, the structural formula of the benzothiazepine compound is shown in the formula I, and the cancer is selected from at least one of liver cancer, intestinal cancer, bone cancer and lung cancer. According to a cell activity experiment, the compound shown in the formula I shows clear and different activities of resisting human liver cancer cells, human lung cancer cells, human osteosarcoma cells and human colorectal cancer cells in vitro. The inventor of the invention finds that the benzothiazepine compound as shown in the formula I has excellent activity on various different types of human tumors for the first time by performing activity screening on a small molecular skeleton, and provides an optional scheme for broad-spectrum anti-cancer drugs.

The present disclosure provides compositions and methods of treating bone cancers, e.g., osteosarcoma in a patient whose age is, for example, at least 2 years old, or at least 12 years old. The method comprises promoting the opening of Cx43 hemichannel in osteocytes by, e.g., using a composition comprising an anti-connexin 43 antibody.

The present disclosure provides compositions and methods for treating osteosarcoma, such as osteosarcoma in a patient who has previously received at least one first-tier osteosarcoma treatment but has failed treatment. The methods comprise promoting the opening of Cx43 hemichannels in bone cells by, for example, using a composition comprising an anticonnexin 43 antibody.

Described herein are crystalline forms of (R)-N-(1-(4-aminobenzyl)-1H-pyrazol-4 -yl)-9-methyl-6-oxo-6,7,8,9-tetrahydropyrido [3′,2′: 4,5]-pyrrolo [1,2-a]pyrazine-2-carboxamide hydrochloride and solvates thereof; pharmaceutical compositions and use thereof in treating cancer such as breast cancer, prostate cancer, lung cancer, brain cancer, skin cancer, bone cancer, ovarian cancer, multiple myeloma and leukemia. Compound (I).

The present invention relates to methods and compositions for the treatment of BAF-related disorders such as melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, and hematologic cancer.

A medical device for in vitro diagnostics is presented for determining personalized therapeutic efficacy in bone cancer and bone metastases from other types of cancer. The invention is a hydrogel that simulates the bone extracellular matrix, comprising bicompatible polymers and micropulverized decellularized bone matrix. A bioink is also presented, which, together with this hydrogel, contains cellular elements obtained from various pathologies present in bone tissue. This mixture is used to create an in vitro diagnostic medical device, for which bioprinting is performed on an automated system. This in vitro diagnostic medical device allows for the evaluation of different chemotherapeutic and immunotherapeutic treatments to personalize the efficacy of the therapies recommended to the patient.

The application belongs to the field of medicine, and particularly relates to application of a benzothiazepine compound in preparation of a cancer treatment drug, wherein the benzothiazepine compound has a structural formula as shown in formula I, and the cancer is at least one selected from liver cancer, intestinal cancer, bone cancer and lung cancer. According to a cell activity experiment of the application, it is found that the compound shown in formula I shows clear and different activities on human liver cancer cells, human lung cancer cells, human osteosarcoma cells and human colorectal cancer cells in vitro. The inventors of the application find, for the first time, through activity screening on a small molecule skeleton, that the benzothiazepine compound shown in formula I has excellent activity on various different types of human tumors, and the benzothiazepine compound provides an optional scheme for a broad-spectrum anticancer drug.

The present invention relates to activin receptor IIA type variants and methods of use thereof. The present invention features a polypeptide comprising an extracellular ActRIIa variant. In some embodiments, the polypeptides of the present invention comprise an extracellular ActRIIa variant fused to an Fc domain monomer or part. The invention also features the use of said polypeptides for the treatment of diseases and conditions involving bone injury, such as primary osteoporosis, secondary osteoporosis, osteopenia, osteosclerosis, fracture, bone cancer or cancer metastasis-associated bone loss, Paget's disease, renal bone dystrophy, treatment-associated bone loss, diet-associated bone loss, osteoporosis-associated bone loss, osteoporosis-associated bone loss, osteoporosis-associated bone loss, osteoporosis-associated bone loss, osteoporosis-associated bone loss, osteoporosis-associated bone loss, osteoporosis-associated bone loss, osteoporosis-associated bone loss, and osteoporosis-associated bone loss. Pharmaceutical compositions and methods for treating bone loss associated with obesity treatment, low gravity associated bone loss, or immobility associated bone loss.

The invention discloses an application of physcion in preparation of analgesic products. The emodin monomethyl ether is used as a single active component, the pain relieving mechanism of the emodin monomethyl ether is deeply discussed, and it is proved that the emodin monomethyl ether can be used as a TRPV1 activity regulator, and expression of TRPV1 is effectively inhibited. Experiments find that the physcion can effectively reduce the twisting frequency of mice caused by acid, significantly increase the pain threshold value of the mice in a hot plate experiment and a CFA inflammatory pain experiment, show an effect of enhancing the pain resistance to heat and inflammation stimulation, and meanwhile, have a significant effect of relieving metastatic bone cancer pain of the mice. The physcion shows a remarkable analgesic effect on animals, and safety or toxic and side effects are not observed.

This patent provides a method for synthesizing new medicinal compounds. The new medicinal compounds can treat cancer, and the cancers include breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia, lung cancer, colon cancer, central nervous system cancer (CNS), melanoma, renal duct cancer, cervical cancer, esophageal cancer, testicular cancer, spleen cancer, kidney cancer, lymphoma, pancreatic cancer, gastric cancer and thyroid cancer. This patent provides an anti-adhesion therapy, that is, using these compounds as regulatory agents or inhibitors of adhesion proteins and angiogenin, inhibiting excessive adhesion and cell attachment, and regulating angiogenesis. These compounds can also be used as cell adhesion receptors, cell circulation and movement, and regulatory agents for inflammatory diseases.

The present disclosure provides compositions and methods of treating bone cancers, e.g., osteosarcoma in patients who previously failed at least one line of therapy for treatment of osteosarcoma. The method comprises promoting the opening of Cx43 hemichannel in osteocytes by, e.g., using a composition comprising an anti-connexin 43 antibody.

The invention provides a PLGA (poly (lactic-co-glycolic acid)-PEG (polyethylene glycol)-phosphonate polymer, a bone targeting nanoparticle as well as a preparation method and application of the bone targeting nanoparticle. According to the preparation method of the PLGA-PEG-phosphonate polymer, no catalyst is needed to participate in the reaction, the reaction can be carried out at room temperature, and the preparation method is a green chemical reaction method and is more suitable for large-scale process production requirements; the bone targeting nanoparticle is formed by self-assembly of the PLGA-PEG-phosphonate polymer and PLGA-PEG, the nanoparticle can be specifically combined with hydroxyapatite in bone tissue to realize targeting of the bone tissue, and the nanoparticle can be used as a drug carrier to deliver drugs to the bone tissue, so that the bone targeting nanoparticle has a good application prospect. And bone tissue related diseases such as osteoporosis, bone cancer and osteoarthritis can be treated.

The invention discloses venenum bufonis, venenum bufonis active ingredients and application of a venenum bufonis active ingredient composition in relieving inflammatory pain and bone cancer pain, and belongs to the technical field of venenum bufonis analgesic active ingredient research. It is found that the venenum bufonis medicinal material can relieve inflammatory pain and bone cancer pain, and it is clear that the main active ingredients of the venenum bufonis medicinal material are cinobufagin and resibufogenin; the cinobufagin and the resibufogenin have a good analgesic effect in a certain ratio range, inflammation pain can be relieved when the mass ratio of the cinobufagin to the resibufogenin is 4: 5-5: 1, and bone cancer pain can be relieved when the mass ratio of the cinobufagin to the resibufogenin is 1: 10-5: 1. The active ingredients cinobufagin and resibufogenin are enlightenment that cinobufagin and resibufogenin can become substitutes of endangered medicinal material venenum bufonis for relieving inflammation pain and bone cancer pain; in addition, it is found for the first time that the analgesic effect of resibufogenin is similar to that of morphine, no addiction exists, and it is prompted that resibufogenin is expected to be developed into a novel analgesic drug.

The present disclosure relates to the field of medicinal chemistry, and specifically to brefeldin A derivatives represent by Formula (I) and its use in the inhibition of tumor proliferation activity. The new compounds provided herein are prominent in the prevention or treatment of hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, lung cancer, Bart's esophageal cancer, gastric cancer, cervical cancer, pancreatic cancer, kidney cancer, endometrial cancer, nasopharyngeal cancer, bone cancer, lymphoma, brain cancer, nerve cancer, oral cancer and colorectal cancer, and have the potential to be developed as novel antitumor agents.

The composition and method for ex vivo expansion of stem cell memory T cells provided by the embodiments of the present disclosure can amplify and culture a cell population with a higher proportion of memory T stem cells, a higher combined proportion of memory T stem cells and central memory T cells, and a higher proportion of natural killer T cells compared to other processes. Additionally, the obtained cell population demonstrates excellent cytotoxic effects against bone cancer and pancreatic cancer cell lines, leading to the production of cell products with enhanced cell therapy efficacy.